California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call
07 oct. 2024 16h30 HE
|
California Resources Corporation
California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call for Wednesday, November 6, 2024 at 1:00 PM ET
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08 août 2024 16h05 HE
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01 août 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08 avr. 2024 16h05 HE
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Child Resistant Closures Market Size to Reach $3.44 Bn by 2028 | The Insight Partners
08 nov. 2023 08h54 HE
|
The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- According to our new research study, titled "Child Resistant Closures Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Material,...
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
04 mai 2023 16h05 HE
|
Immuneering Corporation
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
SAI.TECH Announces Sponsorship and Presence on the 2022 Cryptocurrency Research Conference
19 sept. 2022 08h00 HE
|
SAI.TECH Global Corporation
SINGAPORE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Today, SAI.TECH Global Corporation ("SAI.TECH" OR "SAI", NASDAQ: SAI), a global energy-saving bitcoin mining operator and a clean-tech company that...
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
13 juin 2022 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...